Related Experiment Video
Updated: Jan 10, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Ovarian carcinoma: modification of T4 lymphocytes after surgery and during chemotherapy
M Bogavac1, V Baltić, S Aleksić
1Department of Obstetrics and Gynecology, University of Novi Sad, Yugoslavia.
Objective:
To examine the values of helper/inducer lymphocytes (T4), preoperatively, and during the chemotherapy, 1 and 3 months postoperatively in a prospective randomized study of women with cancer. The study included 30 surgically-treated patients with ovarian cancer at the Department of Obstetrics and Gynecology in Novi Sad, Yugoslavia. In the control group, 20 patients had no malignant ovarian tumor. Patients with ovarian cancer, besides surgical treatment, were treated with chemotherapy (CP protocol). Helper/inducer lymphocytes were defined by monoclonal antibody--CD4, conducted by laser flow cytometry. The average values of T4 lymphocytes in relation to control group (1.09 +/- 0.50), in IIIa, IIIb and IIIc stage of ovarian cancer decreased preoperatively (0.55 +/- 0.26), but increased in stages Ia and Ic (1.12 +/- 0.57) and in stage IV (0.31 +/- 0.51). Post surgery treatment (1 and 3 months) and during chemotherapy (CP protocol), the average values of T4 lymphocytes were lowered in relation to preoperative values.
Related Concept Videos
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

